RxDoctor Payments Data

Veronica Alaniz, PA

Physician Assistant · Corpus Christi, TXNPI 1952621377

Payments from drug & device makers

$1,004in general payments, 2019–2025

Across 49 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$232
  • Bayer$163
  • Abbott$125
  • Lilly USA, LLC$125
  • Novo Nordisk$84
  • Amgen$74
  • plus $202 from 6 others

What the payments were for

  • Food & beverage$1,004100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,004 in reported general payments places this provider in the 65th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$8,400
Medicare patients
47
Services billed
112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin17$32,405
OzempicSemaglutide19$29,113
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$17,510
MounjaroTirzepatide13$15,629
Famotidine48$1,371
Albuterol Sulfate HfaAlbuterol Sulfate33$889
Omeprazole31$844
Duloxetine Hcl20$653
Atorvastatin Calcium67$496
Gabapentin22$493
Losartan Potassium38$477
Montelukast Sodium17$419
Levocetirizine Dihydrochloride39$395
Levothyroxine Sodium46$367
Amlodipine Besylate42$337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$84$29,11319 claims
Lilly USA, LLCMounjaro$125$15,62913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →